In women with ART-treated HIV, there is a 3-fold increase in intramyocardial triglyceride content and reduced diastolic function, leading to higher CVD risk.
Fixed-dose bempedoic acid with ezetimibe lowered LDL-C vs placebo when added to maximally tolerated statin therapy in patients with high CVD risk and hypercholesterolemia.
Women with hypertensive disorders of pregnancy had higher postpartum fasting plasma glucose levels and approximately double the risk for newly diagnosed type 2 diabetes.
For elderly patients taking statins for primary prevention, statin discontinuation is associated with an increased risk for admission for any cardiovascular event.
Results from a phase 3 trial evaluating the efficacy of evinacumab (Regeneron) in the treatment of patients with homozygous familial hypercholesterolemia (HoFH) showed that the investigational angiopoietin-like 3 (ANGPTL3) antibody reduced low-density lipoprotein (LDL) cholesterol by 49%.
Increased variations of body mass index and high-density lipoprotein cholesterol during childhood are independent risk factors for the development of diabetes.
Benefit of simvastatin-ezetimibe combo after acute coronary syndrome greatest for patients ≥75 years
Moderate caloric restriction for 2 years may improve several cardiovascular risk factors in young and middle-aged healthy individuals.
The Endocrine Society published a clinical practice guideline cosponsored by the American Diabetes Association and the European Society of Endocrinology regarding the primary prevention of ASCVD and T2D.
Although high-density lipoprotein cholesterol has been deemed the “good cholesterol,” this label may be misleading and outdated given that there is little evidence to support a causal relationship with CVD risk reduction.
In addition to being manufactured outside of the controls required by current Good Manufacturing Practices, these products are also being marketed for diseases without FDA approval.